Back to results
US 2025/0177578 A1Published application
Psma-binding agents and uses thereof
AssigneeThe Johns Hopkins University
InventorsMartin G. Pomper, Ronnie Charles Mease, Ying Chen
Life of this patent
Estimating the term…
Abstract
Prostate-specific membrane antigen (PSMA) binding compounds having radioisotope substituents are described, as well as chemical precursors thereof. Compounds include pyridine containing compounds, compounds having phenylhydrazine structures, and acylated lysine compounds. The compounds allow ready incorporation of radionuclides for single photon emission computed tomography (SPECT) and positron emission tomography (PET) for imaging, for example, prostate cancer cells and angiogenesis.
Claims24
A compound having the structure
- wherein
- Z is tetrazole or CO2Q;
- each Q is independently selected from hydrogen or a protecting group;
- and wherein
- (A) m is 0, 1, 2, 3, 4, 5, or 6;
- R is a pyridine ring selected from the group consisting of
- wherein X is fluorine, iodine, a radioisotope of fluorine, a radioisotope of iodine, chlorine, bromine, a radioisotope of bromine, a radioisotope of astatine, NO2, NH2, N+(R2)3, Sn(R2)3, Si(R2)3, Hg(R2), B(OH)2, —NHNH2, —NHN═CHR3, —NHNH—CH2R3;
- n is 1, 2, 3, 4, or 5;
- Y is O, S, N(R′), C(O), NR′C(O), C(O)N(R′), OC(O), C(O)O, NR′C(O)NR′, NR′C(S)NR′, NR′S(O)2, S(CH2)p, NR′(CH2)p, O(CH2)p, OC(O)CHR8NHC(O), or a covalent bond;
- wherein p is 1, 2, or 3, R is H or C1-C6 alkyl, and R8 is hydrogen, alkyl, aryl or heteroaryl, each of which may be substituted;
- R2 is C1-C6 alkyl;
- and
- R3 is alkyl, alkenyl, alkynyl, aryl, or heteroaryl each of which is substituted by fluorine, iodine, a radioisotope of fluorine, a radioisotope of iodine, chlorine, bromine, a radioisotope of bromine, or a radioisotope of astatine, NO2, NH2, N+(R2)3, Sn(R2)3, Si(R2)3, Hg(R2), or B(OH)2;
- OR
- (B) m is 0, 1, 2, 3, 4, 5, or 6;
- Y is O, S, N(R′), C(O), NR′C(O), C(O)N(R′), OC(O), C(O)O, NR′C(O)NR′, NR′C(S)NR′, NR′S(O)2, S(CH2)p, NR′—(CH2)p, O(CH2)p, OC(O)CHR8NHC(O), NHC(O)CHR8NHC(O), or a covalent bond;
- wherein p is 1, 2, or 3, R′ is H or C1-C6 alkyl, and R8 is hydrogen alkyl, aryl or heteroaryl, each of which may be substituted;
- R is
- wherein
- X′ is selected from the group consisting of NHNH2, —NHN═CHR3, and —NHNH—CH2R3;
- wherein R3 is alkyl, alkenyl, alkynyl, aryl, or heteroaryl each of which is substituted by fluorine, iodine, a radioisotope of fluorine, a radioisotope of iodine, bromine, a radioisotope of bromine, or a radioisotope of astatine, NO2, NH2, N+(R2)3, Sn(R2)3, Si(R2)3, Hg(R2), or B(OH)2;
- R2 is C1-C6 alkyl;
- n is 1, 2, 3, 4, or 5;
- OR
- (C) m is 4,
- Y is NR′, and
- R is
- wherein
- G is O, NR′ or a covalent bond;
- R′ is H or C1-C6 alkyl;
- p is 1, 2, 3, or 4, and
- R7 is selected from the group consisting of NH2, N═CHR3, NH—CH2R3, wherein R3 is alkyl, alkenyl, alkynyl, aryl, or heteroaryl each of which is substituted by fluorine, iodine, a radioisotope of fluorine, a radioisotope of iodine, chlorine, bromine, a radioisotope of bromine, or a radioisotope of astatine, NO2, NH2, N+(R2)3, Sn(R2)3, Si(R2)3, Hg(R2), B(OH)2;
- and R2 is C1-C6 alkyl.
30 more elements
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.